Sandbox/002: Difference between revisions
Gerald Chi (talk | contribs) m (→Staphylococcus) |
Gerald Chi (talk | contribs) m (→Staphylococcus) |
||
Line 468: | Line 468: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg/day IV q8—12h x 3—5 days'''''<sup>¶</sup> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg/day IV q8—12h x 3—5 days'''''<sup>¶</sup> | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 80%; background: #F5F5F5;" align=left | <sup>†</sup> For complicated right-sided IE and for left-sided IE; for uncomplicated right-sided IE, 2 weeks. <BR> <sup>¶</sup> Gentamicin dosage should be adjusted to achieve peak serum concentration of 3—4 μg/ml and trough serum concentration of less than 1 μg/ml when 3 divided doses are used; nomogram used for single daily dosing; other potentially nephrotoxic drugs (e.g., nonsteroidal anti-inflammatory drugs) should be used with caution in patients receiving gentamicin therapy. <BR> <sup>‡</sup> For penicillin-allergic (nonanaphylactoid type) patients; consider skin testing for oxacillin-susceptible staphylococci and questionable history of immediate-type hypersensitivity to penicillin. <BR> <sup>§</sup> Cephalosporins should be avoided in patients with anaphylactoid-type hypersensitivity to beta-lactams; vancomycin should be used in these cases. | | style="padding: 0 5px; font-size: 80%; background: #F5F5F5;" align=left | <sup>†</sup> For complicated right-sided IE and for left-sided IE; for uncomplicated right-sided IE, 2 weeks. <BR> <sup>¶</sup> Gentamicin should be administered in close proximity to vancomycin, nafcillin, or oxacillin dosing. Gentamicin dosage should be adjusted to achieve peak serum concentration of 3—4 μg/ml and trough serum concentration of less than 1 μg/ml when 3 divided doses are used; nomogram used for single daily dosing; other potentially nephrotoxic drugs (e.g., nonsteroidal anti-inflammatory drugs) should be used with caution in patients receiving gentamicin therapy. <BR> <sup>‡</sup> For penicillin-allergic (nonanaphylactoid type) patients; consider skin testing for oxacillin-susceptible staphylococci and questionable history of immediate-type hypersensitivity to penicillin. <BR> <sup>§</sup> Cephalosporins should be avoided in patients with anaphylactoid-type hypersensitivity to beta-lactams; vancomycin should be used in these cases. | ||
|} | |} | ||
|} | |} | ||
Line 492: | Line 492: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 3—5 days'''''<sup>¶</sup> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 3—5 days'''''<sup>¶</sup> | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 80%; background: #F5F5F5;" align=left | <sup>†</sup> For complicated right-sided IE and for left-sided IE; for uncomplicated right-sided IE, 2 weeks. <BR> <sup>¶</sup> Gentamicin dosage should be adjusted to achieve peak serum concentration of 3—4 μg/ml and trough serum concentration of less than 1 μg/ml when 3 divided doses are used; nomogram used for single daily dosing; other potentially nephrotoxic drugs (e.g., nonsteroidal anti-inflammatory drugs) should be used with caution in patients receiving gentamicin therapy. <BR> <sup>‡</sup> For penicillin-allergic (nonanaphylactoid type) patients; consider skin testing for oxacillin-susceptible staphylococci and questionable history of immediate-type hypersensitivity to penicillin. <BR> <sup>§</sup> Cephalosporins should be avoided in patients with anaphylactoid-type hypersensitivity to beta-lactams; vancomycin should be used in these cases. | | style="padding: 0 5px; font-size: 80%; background: #F5F5F5;" align=left | <sup>†</sup> For complicated right-sided IE and for left-sided IE; for uncomplicated right-sided IE, 2 weeks. <BR> <sup>¶</sup> Gentamicin should be administered in close proximity to vancomycin, nafcillin, or oxacillin dosing. Gentamicin dosage should be adjusted to achieve peak serum concentration of 3—4 μg/ml and trough serum concentration of less than 1 μg/ml when 3 divided doses are used; nomogram used for single daily dosing; other potentially nephrotoxic drugs (e.g., nonsteroidal anti-inflammatory drugs) should be used with caution in patients receiving gentamicin therapy. <BR> <sup>‡</sup> For penicillin-allergic (nonanaphylactoid type) patients; consider skin testing for oxacillin-susceptible staphylococci and questionable history of immediate-type hypersensitivity to penicillin. <BR> <sup>§</sup> Cephalosporins should be avoided in patients with anaphylactoid-type hypersensitivity to beta-lactams; vancomycin should be used in these cases. | ||
|} | |} | ||
|} | |} | ||
Line 506: | Line 506: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 600 mg IV q12h x 8 weeks''''' <BR> OR <BR> ▸ '''''[[Daptomycin]] 6 mg/kg IV q24h x 2—6 weeks''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 600 mg IV/PO q12h x 8 weeks''''' <BR> OR <BR> ▸ '''''[[Daptomycin]] 6 mg/kg IV q24h x 2—6 weeks''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 80%; background: #F5F5F5;" align=left | <sup>ǁ</sup> Vancomycin doses should not exceed 2 g per 24 h, unless serum concentrations are inappropriately low. Dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/ml and a trough concentration range of 10–15 μg/ml. Vancomycin should be infused during course of at least 1 h to reduce risk of histamine-release red man syndrome. | | style="padding: 0 5px; font-size: 80%; background: #F5F5F5;" align=left | <sup>ǁ</sup> Vancomycin doses should not exceed 2 g per 24 h, unless serum concentrations are inappropriately low. Dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/ml and a trough concentration range of 10–15 μg/ml. Vancomycin should be infused during course of at least 1 h to reduce risk of histamine-release red man syndrome. | ||
Line 522: | Line 522: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 10 mg/kg IV q8h x 8 weeks''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 10 mg/kg IV/PO q8h x 8 weeks''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 80%; background: #F5F5F5;" align=left | <sup>ǁ</sup> Vancomycin doses should not exceed 2 g per 24 h, unless serum concentrations are inappropriately low. Dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/ml and a trough concentration range of 10–15 μg/ml. Vancomycin should be infused during course of at least 1 h to reduce risk of histamine-release red man syndrome. | | style="padding: 0 5px; font-size: 80%; background: #F5F5F5;" align=left | <sup>ǁ</sup> Vancomycin doses should not exceed 2 g per 24 h, unless serum concentrations are inappropriately low. Dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/ml and a trough concentration range of 10–15 μg/ml. Vancomycin should be infused during course of at least 1 h to reduce risk of histamine-release red man syndrome. | ||
|} | |} | ||
|} | |} | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Staphylococcal PVE, Oxacillin Susceptible, Adult}} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''<sup>†</sup> | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 2 g IV q4h x ≥6 weeks''''' <BR> OR <BR> ▸ '''''[[Oxacillin]] 2 g IV q4h x ≥6 weeks''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampin]] 300 mg IV/PO q8h x ≥6 weeks''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg/day IV q8—12h x 2 weeks'''''<sup>¶</sup> | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 10 mg/kg IV q8h x 8 weeks''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 80%; background: #F5F5F5;" align=left | <sup>†</sup> Penicillin G 24 million U/24 h IV in 4 to 6 equally divided doses may be used in place of nafcillin or oxacillin if strain is penicillin susceptible (minimum inhibitory concentration ≤0.1 μg/mL) and does not produce β-lactamase; vancomycin should be used in patients with immediate-type hypersensitivity reactions to β-lactam antibiotics; cefazolin may be substituted for nafcillin or oxacillin in patients with non–immediate-type hypersensitivity reactions to penicillins. <BR> <sup>¶</sup> Gentamicin should be administered in close proximity to vancomycin, nafcillin, or oxacillin dosing. Gentamicin dosage should be adjusted to achieve peak serum concentration of 3—4 μg/ml and trough serum concentration of less than 1 μg/ml when 3 divided doses are used; nomogram used for single daily dosing; other potentially nephrotoxic drugs (e.g., nonsteroidal anti-inflammatory drugs) should be used with caution in patients receiving gentamicin therapy. | |||
|} | |||
|} | |||
Revision as of 01:20, 7 March 2014
Endocarditis Microchapters |
Diagnosis |
---|
Treatment |
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
Case Studies |
Sandbox/002 On the Web |
Pathogen-Based Therapy Adapted from Circulation 2005;111(23):e394-434.[1] and Circulation 2008;118(15):e523-661.[2]
Viridans Streptococci or Streptococcus bovis
▸ Click on the following categories to expand treatment regimens.
Native Valve Endocarditis ▸ Highly PCN Susceptible, Adult ▸ Highly PCN Susceptible, Pediatric ▸ Relatively PCN Resistant, Adult ▸ Relatively PCN Resistant, Pediatric ▸ Highly PCN Resistant Prosthetic Valve Endocarditis ▸ PCN Susceptible, Adult ▸ PCN Susceptible, Pediatric ▸ PCN Resistant, Adult ▸ PCN Resistant, Pediatric |
|
Streptococcus pneumoniae, Streptococcus pyogenes, and Groups B, C, and G Streptococci
▸ Click on the following categories to expand treatment regimens.
Streptococcus pneumoniae ▸ PCN Susceptible ▸ PCN Resistant, Without Meningitis ▸ PCN Resistant, With Meningitis Streptococcus pyogenes ▸ S. pyogenes Endocarditis Group B, C, and G Streptococcus ▸ Group B, C, and G Streptococcus Endocarditis |
|
Staphylococcus
▸ Click on the following categories to expand treatment regimens.
Native Valve Endocarditis ▸ Oxacillin Susceptible, Adult ▸ Oxacillin Susceptible, Pediatric ▸ Oxacillin Resistant, Adult ▸ Oxacillin Resistant, Pediatric Prosthetic Valve Endocarditis ▸ Oxacillin Susceptible, Adult ▸ Oxacillin Susceptible, Pediatric ▸ Oxacillin Resistant, Adult ▸ Oxacillin Resistant, Pediatric |
|
References
- ↑ Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter
|month=
ignored (help) - ↑ Bonow, RO.; Carabello, BA.; Chatterjee, K.; de Leon, AC.; Faxon, DP.; Freed, MD.; Gaasch, WH.; Lytle, BW.; Nishimura, RA. (2008). "2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (13): e1–142. doi:10.1016/j.jacc.2008.05.007. PMID 18848134. Unknown parameter
|month=
ignored (help)